Malignant pleural mesothelioma [PDF]
Lung India, 2009 Malignant mesothelioma is one of the rare tumors of pleura. One such case in a 57-year-old male, who presented with hemorrhagic pleural effusion and had no history of asbestos exposure, is reported here. The rarity, unusual presentation, and implications
Rao Sukhesh
doaj +7 more sources
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor [PDF]
Case Reports in Pulmonology, 2016 Biphasic malignant pleural mesothelioma is a rare malignant tumor, usually presenting as a pleural-based mass in a patient with history of chronic asbestos exposure.
James Benjamin Gleason +2 more
doaj +2 more sources
Massive Pleural Effusion Leads to the Revelation of Malignant Pleural Mesothelioma: A Case Report
Jurnal RespirasiIntroduction: Malignant mesothelioma is a cancer that develops from the thin layer of tissue covering visceral organs (mesothelium). Up to 80% of malignant mesothelioma cases are caused by asbestos exposure.
Gede Adi Prasetya Wijaya +3 more
doaj +2 more sources
The experience of mesothelioma in Northern England [PDF]
, 2007 Mesothelioma is a potentially preventable fatal disease causing almost 2000 deaths/year in the UK, increasing in incidence, and lacking effective treatments.
Clayson, Helen
core +6 more sources
Multimodal treatment for resectable epithelial type malignant pleural mesothelioma [PDF]
World Journal of Surgical Oncology, 2004 Background Malignant pleural mesothelioma is a rare malignancy. The outcome remains poor despite complete surgical resection. Patients and methods Eleven patients with histologicaly proven epithelial type malignant pleural mesothelioma undergoing ...
Fukuyama Yasuro +6 more
doaj +2 more sources
Integrative Bioinformatics and Machine Learning Approaches for Biomarker and Pathway Discovery in Malignant Pleural Mesothelioma. [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Malignant pleural mesothelioma (MPM) is a highly aggressive thoracic cancer with limited treatment options and poor prognosis. Aims This study employed an integrative transcriptomic and computational approach to uncover potential biomarkers for MPM.
Rohman ML, Biswas S.
europepmc +2 more sources
Malignant pleural mesothelioma [PDF]
Annals of Oncology, 1998 The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is expected to peak between 2010 and 2020. Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest.
P, Baas, H, Schouwink, F A, Zoetmulder
openaire +4 more sources
Malignant pleural mesothelioma [PDF]
American Journal of Health-System Pharmacy, 2012 PURPOSE The etiology, diagnosis, staging, and management of malignant pleural mesothelioma (MPM) are reviewed, with an emphasis on clinical trials of newer approaches to first-line, second-line, and adjuvant chemotherapy.In the past decade, more effective chemotherapy regimens have been developed for patients with MPM, a rapidly progressing disease ...
Sheree E, Chen, Makala B, Pace
openaire +4 more sources
Immunotherapy in Malignant Pleural Mesothelioma [PDF]
Frontiers in Oncology, 2020 The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most important immunotherapy-based research performed and put a focus on the future of MPM. PD-
Gooijer, C.J. de +3 more
openaire +4 more sources
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. [PDF]
, 2011 BACKGROUND: The effects of extra-pleural pneumonectomy (EPP) on survival and quality of life in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed in a randomised trial.
Loic Lang-Lazdunski +41 more
core +1 more source